Orna Therapeutics is a developer of RNA therapeutics that utilize molecular design and delivery technologies to unlock the full therapeutic potential of RNA to treat a variety of diseases, including cancer, autoimmune and genetic diseases. Recently, Orna Therapeutics announced the completion of a $221 million Series B financing, led by Merck and followed by MPM Capital and its subsidiary BioImpact Capital. The financing will be used to advance the in situ CAR-T therapy (isCAR) developed by Orna Therapeutics into the clinic, as well as the development of other preclinical programs.
This article is reproduced from: https://www.itjuzi.com/investevent/13510569
This site is for inclusion only, and the copyright belongs to the original author.